Clinical trials: ifosfamide
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL).
- Trial name
- EPCORE™ NHL-2 (NCT04663347)
- Testing
- rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine
- Where
- 57 sites in United States, Australia and 11 more
- Volunteers
- 543 people
- Sponsor
- Genmab
Endometrial Cancer, Kidney Cancer
Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Endometrial Cancer, Kidney Cancer, Metastatic Cancer, Ovarian Cancer
- Trial name
- NCT00002764
- Testing
- filgrastim, doxorubicin hydrochloride, ifosfamide
- Where
- Sweden
- Volunteers
- 340 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Other Disorders of Soft Tissues
Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment
To evaluate the effectiveness, safety and tolerability of Endostar (recombinant human endostatin) combined with AI chemotherapy in adjuvant treatment after radical resection of recurrent soft tissue sarcoma.
- Trial name
- NCT04699214
- Testing
- Endostar (recombinant human endostatin injection), Chemotherapy AI
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Yong Chen
Leukemia, Lymphoma
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00005977
- Testing
- filgrastim, cyclophosphamide, cytarabine
- Where
- 119 sites in United States, Australia and 4 more
- Volunteers
- 83 people
- Sponsor
- Children's Oncology Group
Ewing Sarcoma, Risk Stratification
Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study
The aim is to evaluate the outcome and safety of risk-stratification oriented treatment for pediatric Ewing sarcoma in multicenters .
- Trial name
- NCT06451302
- Testing
- cyclophosphamide, adriamycin, vincristine，Ifosfamide，etoposide
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Yizhuo Zhang
Malignancy, Cancer
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
This an an open-label study to define the safety profile and the maximum tolerated dose and confirm the clinical effective dose of palifosfamide-tris given intravenously in combination with etoposide and carboplatin in a wide…
- Conditions
- Malignancy, Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT01242072
- Testing
- palifosfamide-tris
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Alaunos Therapeutics
Advanced Cancer
Study of Oral Palifosfamide Tris in Solid Tumors
The study of maximum tolerated dose and safety of oral palifosfamide tris capsules in advanced, refractory, solid tumors
- Trial name
- NCT00607711
- Testing
- oral palifosfamide tris
- Sponsor
- Alaunos Therapeutics
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage…
- Trial name
- Pola-R-ICE (NCT04833114)
- Testing
- Polatuzumab Vedotin, Mabthera, Ifosfamide
- Where
- 64 sites in Austria, Germany and 2 more
- Volunteers
- 306 people
- Sponsor
- GWT-TUD GmbH
Soft Tissue Sarcoma
Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma
This study is a open-lable , single arm，single center, phase II clinical study. Target population is patients with high-risk Soft tissue sarcoma.
- Trial name
- NCT04606108
- Testing
- Camrelizumab in Combination With Neoadjuvant Chemotherapy
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-sen University
Lymphoma
Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00025064
- Testing
- bleomycin sulfate, chlorambucil, cisplatin
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 260 people
- Sponsor
- Children's Cancer and Leukaemia Group
Lymphoma, Hodgkin's Lymphoma
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
To determine the recommended phase 2 dose of chemotherapy in combination with Pembrolizumab in subjects with advanced lymphoma and determine the complete response rate.
- Conditions
- Lymphoma, Hodgkin's Lymphoma, Non-hodgkin's Lymphoma
- Trial name
- NCT02408042
- Testing
- Pembrolizumab, Etoposide, Ifosfamide
- Where
- United States
- Sponsor
- Western Regional Medical Center
Diffuse Large B Cell Lymphoma
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
A single-center, open, single-arm clinical study of the efficacy and safety of a novel targeted agent in combination with R-ICE in the treatment of relapsed and refractory diffuse Large B-cell lymphoma.
- Trial name
- R-ICE+X (NCT05348213)
- Testing
- Zanubrutinib plus R-ICE, Decitabine plus R-ICE, Chidamide plus R-ICE
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Ruijin Hospital
Mature B-cell Non-Hodgkin Lymphoma
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
The trial B-NHL 2013 is a collaborative prospective, multi-national, multi-center, randomized trial with participating centers of the NHL-BFM group (Austria, Switzerland, Czech Republic, Germany) and the Scandinavian NOPHO group…
- Trial name
- B-NHL 2013 (NCT03206671)
- Testing
- Rituximab window, Additional doses of Rituximab, Cyclophosphamide
- Where
- 88 sites in Austria, Czechia and 6 more
- Volunteers
- 650 people
- Sponsor
- University Hospital Muenster
Small Cell Lung Cancer
A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer
Phase 1 : To evaluate MTD(Maximal tolerated dose)and DLT(Dose limiting Toxicity) of Belotecan and Ifosfamide. Phase 2 : To analyse efficacy and toxicity of Belotecan and Ifosfamide.
- Trial name
- NCT01784107
- Testing
- Belotecan and Ifosfamide
- Where
- South Korea
- Volunteers
- 45 people
- Sponsor
- Gachon University Gil Medical Center
Lymphoma, Large Cell, Lymphoma, Non-Hodgkin
Large Cell Lymphoma Pilot Study III
The main purpose of this study is to find out if it is feasible to deliver a multi-agent chemotherapy regimen which features a shorter, more intensive, immunophenotype-directed approach, and includes an intensification phase with…
- Trial name
- NCT00187070
- Testing
- Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine, Stem cell transplant,, Radiation Therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- St. Jude Children's Research Hospital
Extra Cranial Non Seminomateous Malignant Germ Cell Tumour
A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent
The main objective is to assess the benefit-risk ratio of a risk-adapted strategy for treatment of extra cranial NSMGCT in children and adolescent.
- Trial name
- NCT02104986
- Testing
- Velbe-Bleomycin-Cisplatin, Vepeside-ifosfamide-Cisplatin
- Where
- 27 sites in France
- Volunteers
- 117 people
- Sponsor
- Centre Leon Berard
Classical Hodgkin Lymphoma
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
The primary objective of this study is to evaluate the efficacy of tislelizumab in participants with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Progression-free Survival (PFS) as assessed by…
- Trial name
- NCT04486391
- Testing
- Tislelizumab, Salvage Chemotherapy
- Where
- 7 sites in China
- Volunteers
- 3 people
- Sponsor
- BeiGene
Germ Cell Tumor
Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors
High-dose chemotherapy with autologous hematopoietic stem-cell transplantation is a standard salvage treatment used in adults with germ cell tumors (Einhorn et al, J Clin Oncol 2007).
- Trial name
- TAXIFIII (NCT01966913)
- Testing
- Bevacizumab, ICE chemotherapy regimen
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with rituximab, ifosfamide, carboplatin, and etoposide and to see how well they work in treating patients with relapsed or…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Contiguous Stage II Mantle Cell Lymphoma
- Trial name
- NCT00601718
- Testing
- vorinostat, rituximab, ifosfamide
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Washington
Malignant Bone Tumor
Narlumosbartmab Combined With Neoadjuvant Chemotherapy in Bone-derived Malignancies With Osteolytic Lesions and Multinucleated Giant Cells
Malignant tumor of bone is rare with poor prognosis. Surgery is the main treatment for non- metastatic bone tumor. Although neoadjuvant chemotherapy for non-metastatic bone tumor cannot improve survival rate based on adjuvant…
- Trial name
- NCT06302465
- Testing
- narlumosbartmab plus doxorubicin、cisplatin、methotrexate、ifosfamide, doxorubicin、cisplatin、methotrexate、ifosfamide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital